| abstract |
Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the combination of peptides is provided as a composition, eg, a pharmaceutical composition, while in other embodiments, the combination of peptides is provided as a kit. In other embodiments, the combination of peptides is provided as a conjugate, eg, a fusion peptide, a heterodimer. In particular aspects, the GIP agonist peptide is an analog of native human glucagon. In particular aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently linked to the glucagon antagonist peptide via a linker. Further provided are methods of treating metabolic disorders such as diabetes and obesity comprising administering the peptide compositions described herein. |